Veracyte Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Veracyte stock.
View analyst ratings for Veracyte or view top-rated stocks.

7 Wall Street analysts have issued 12 month price targets for Veracyte's stock. Their VCYT stock forecasts range from $26.00 to $59.00. On average, they expect Veracyte's stock price to reach $42.14 in the next twelve months. This suggests a possible upside of 76.1% from the stock's current price.
View analysts' price targets for Veracyte or view top-rated stocks among Wall Street analysts.

Veracyte's stock was trading at $41.20 at the beginning of the year. Since then, VCYT stock has decreased by 41.9% and is now trading at $23.93.
View the best growth stocks for 2022 here.

Veracyte is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Veracyte.

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.03. The biotechnology company earned $67.78 million during the quarter, compared to analyst estimates of $61.98 million. Veracyte had a negative net margin of 19.22% and a negative trailing twelve-month return on equity of 4.09%. During the same quarter last year, the firm posted ($0.11) EPS.
View Veracyte's earnings history.

Veracyte updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $265.00 million-$275.00 million, compared to the consensus revenue estimate of $270.30 million.

Some companies that are related to Veracyte include Guardant Health (GH), Natera (NTRA), Elekta AB (publ) (EKTAY), Fulgent Genetics (FLGT), CareDx (CDNA), RadNet (RDNT), Invitae (NVTA), Castle Biosciences (CSTL), Burning Rock Biotech (BNR), Viridian Therapeutics (VRDN), DermTech (DMTK), Personalis (PSNL), Celcuity (CELC), Genetron (GTH) and MDxHealth (MDXH).
View all of VCYT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VCYT stock can currently be purchased for approximately $23.93.

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.71 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75,560,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

Veracyte employs 761 workers across the globe.

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for Veracyte is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.